FDA.reportPublic FDA data

Potassium Chloride in Sodium Chloride Injection, USP in Plastic Container

Manufacturer
Fresenius Kabi USA, LLC | HP Halden Pharma AS
Effective date
2024-04-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
full-release
Hydrated at
2026-05-31 21:02:52

Label at a glance#

ProductPotassium Chloride in Sodium Chloride
Active ingredientSodium Chloride, Potassium Chloride
Label structure15 sections

Indications and uses

Potassium Chloride in Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.

Dosage and administration

Important Administration Instructions Potassium Chloride in Sodium Chloride Injection, USP is intended for intravenous infusion using sterile equipment. To avoid life threatening hyperkalemia, do not administer Potassium Chloride in Sodium Chloride Injection, USP as an intravenous push (i.e., intravenous injection manually with a syringe connected to the intravenous access) without a quantitative infusion device (...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

freeflex Logofreeflex Logo

DESCRIPTION

DESCRIPTION SECTION

Potassium Chloride in Sodium Chloride Injection, USP is a sterile, nonpyrogenic, solution for fluid and electrolyte replenishment in a single dose container for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH and ionic concentration are shown in Table 1.

Table 1
*Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage.
Size (mL) Composition (g/L) *Osmolarity (mOsmol/L) (Calc.) pH Ionic Concentration (mEq/L)
Sodium Chloride, USP NaCl
Potassium Chloride, USP KCl
Sodium PotassiumChloride
20 mEq/L Potassium Chloride in 0.45% Sodium Chloride Injection, USP 1000 4.5 1.5 194 5.5
(3.5 to 6.5) 		77 2097
20 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection, USP 1000 9 1.5 348 5.5
(3.5 to 6.5) 		154 20174
40 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection, USP 1000 9 3 388 5.5
(3.5 to 6.5) 		154 40194

The flexible plastic container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers (free flex ® bag). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container's chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Potassium Chloride in Sodium Chloride Injection, USP has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Potassium Chloride in Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Potassium Chloride in Sodium Chloride Injection, USP is contraindicated in patients with:

  • Known hypersensitivity to potassium chloride and/or sodium chloride (see WARNINGS).
  • Clinically significant hyperkalemia (see WARNINGS).

WARNINGS

WARNINGS SECTION

Hypersensitivity

SPL UNCLASSIFIED SECTION

Hypersensitivity and infusion reactions, including anaphylaxis and chills, have been reported with products containing potassium chloride and sodium chloride. Stop the infusion immediately if signs or symptoms of a hypersensitivity or infusion reaction develops. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

Electrolyte Imbalances

SPL UNCLASSIFIED SECTION

Hyperkalemia

SPL UNCLASSIFIED SECTION

Potassium-containing solutions, including Potassium Chloride in Sodium Chloride Injection, USP may increase the risk of hyperkalemia. Hyperkalemia can be asymptomatic and manifest only by increased serum potassium concentrations and/or characteristic electrocardiographic (ECG) changes. Cardiac conduction disorders (including complete heart block) and other cardiac arrhythmias, some fatal, can develop at any time during hyperkalemia. Continuous electrocardiogram (ECG) monitoring may be necessary to aid in the detection of cardiac arrhythmias due to hyperkalemia (see ADVERSE REACTIONS).

To avoid life threatening hyperkalemia, do not administer Potassium Chloride in Sodium Chloride Injection, USP as an intravenous push (i.e., intravenous injection manually with a syringe connected to the intravenous access) without a quantitative infusion device.

Patients at increased risk of developing hyperkalemia and cardiac arrhythmias include those:

  • with conditions predisposing to hyperkalemia and/or associated with increased sensitivity to potassium, such as patients with severe renal impairment, acute dehydration, extensive tissue injury or burns, certain cardiac disorders such as congestive heart failure or atrioventricular (AV) block (especially if they receive digoxin).
  • who are at risk of experiencing hyperosmolality, acidosis, or undergoing correction of alkalosis (conditions associated with a shift of potassium from intracellular to extracellular space).
  • treated concurrently or recently with agents or products that can cause or increase the risk of hyperkalemia (see DRUG INTERACTIONS).
  • with cardiac arrhythmias.

Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients with, or at risk for, hyperkalemia. If use cannot be avoided, use a product with a low amount of potassium chloride, infuse slowly and monitor serum potassium concentrations and ECGs.

Hypernatremia and Hyperchloremia

SPL UNCLASSIFIED SECTION

Electrolyte imbalances such as hypernatremia, hyperchloremia, and metabolic acidosis may occur with Potassium Chloride in Sodium Chloride Injection, USP.

Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.

Certain medications, such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention, see DRUG INTERACTIONS.

Avoid Potassium Chloride in Sodium Chloride Injection, USP in patients with, or at risk for, hypernatremia or hyperchloremia. If use cannot be avoided, monitor serum sodium and chloride concentrations and acid-base balance.

Rapid correction of hypernatremia is potentially dangerous with risk of serious neurologic complications. Excessively rapid correction of hypernatremia is also associated with a risk for serious neurologic complications such as osmotic demyelination syndrome (ODS) with risk of seizures and cerebral edema.

Hyponatremia

SPL UNCLASSIFIED SECTION

Potassium Chloride in Sodium Chloride Injection, USP may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.

The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH) treated with high volume of hypotonic Potassium Chloride in Sodium Chloride Injection, USP.

The risk for hyponatremia is increased in pediatric patients, elderly patients, postoperative patients, those with psychogenic polydipsia, and in patients treated with medications that increase the risk of hyponatremia (such as diuretics, certain antiepileptic and psychotropic medications). See DRUG INTERACTIONS.

Patients at increased risk for developing complications of hyponatremia such as hyponatremic encephalopathy, include pediatric patients, women (in particular, premenopausal women), patients with hypoxemia, and patients with underlying central nervous system disease. Avoid Potassium Chloride in Sodium Chloride Injection, USP in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations.

Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications. Brain adaptations reducing risk of cerebral edema make the brain vulnerable to injury when chronic hyponatremia is too rapidly corrected, which is known as osmotic demyelination syndrome (ODS). To avoid complications, monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.

Fluid Overload

SPL UNCLASSIFIED SECTION

Depending on the volume and rate of infusion, and the patient’s underlying clinical condition, the intravenous administration of Potassium Chloride in Sodium Chloride Injection, USP can cause electrolyte disturbances such as overhydration/hypervolemia and congested states including central (e.g., pulmonary edema) and peripheral edema.

Avoid Potassium Chloride in Sodium Chloride Injection, USP in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor fluid balance, electrolyte concentrations and acid base balance as needed and especially during prolonged use.

PRECAUTIONS

PRECAUTIONS SECTION

Patients with Severe Renal Impairment

SPL UNCLASSIFIED SECTION

Administration of sodium and potassium in patients with or at risk of severe renal impairment, may result in hypernatremia, hyperkalemia and/or fluid overload (see WARNINGS). Avoid Potassium Chloride in Sodium Chloride Injection, USP in patients with severe renal impairment. If use cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.

Drug Interactions

DRUG INTERACTIONS SECTION

Lithium

SPL UNCLASSIFIED SECTION

Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Monitor serum lithium concentrations during concomitant use.

Other Products that Cause Hyperkalemia

SPL UNCLASSIFIED SECTION

Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and tacrolimus). If use cannot be avoided, monitor serum potassium concentrations.

Other Products that Affect Fluid and/or Electrolyte Balance

SPL UNCLASSIFIED SECTION

Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concomitantly with medications associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided, monitor serum electrolytes, fluid balance, and acid-base balance.

Other Drugs that Increase the Risk of Hyponatremia

SPL UNCLASSIFIED SECTION

Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia.

Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be avoided, monitor serum sodium concentrations.

Pregnancy

PREGNANCY SECTION

There are no adequate and well controlled studies from the use of Potassium Chloride in Sodium Chloride Injection, USP in pregnant or lactating women and animal reproduction studies have not been conducted with this drug. Therefore, it is also not known whether Potassium Chloride in Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium Chloride in Sodium Chloride Injection, USP should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Potassium Chloride in Sodium Chloride Injection, USP is administered to a nursing mother.

Pediatric Use

PEDIATRIC USE SECTION

The use of Potassium Chloride in Sodium Chloride Injection, USP in pediatric patients is based on clinical practice. (See DOSAGE AND ADMINISTRATION). Safety and effectiveness of Potassium Chloride in Sodium Chloride Injection, USP in pediatric patients have not been established by adequate and well-controlled studies.

Pediatric patients are at increased risk of developing hyponatremia as well as for developing encephalopathy as a complication of hyponatremia (see WARNINGS).

Geriatric Use

GERIATRIC USE SECTION

Geriatric patients are at increased risk of developing electrolyte imbalances. Potassium Chloride in Sodium Chloride Injection, USP is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Consider monitoring renal function in elderly patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following adverse reactions associated with the use of Potassium Chloride in Sodium Chloride Injection, USP were identified in clinical trials or postmarketing reports. Because postmarketing reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.

General disorders and administration site conditions: Chills, and infusion site pain.

Hypersensitivity reactions: generalized papules and erythema, rash, fever, vomiting, hypertension, tachycardia.

Metabolism and nutrition disorders: Hyperkalemia, hyponatremia, hypernatremia, hyperchloremia acidosis, fluid overload.

Cardiac disorders: Cardiac arrest as a manifestation of rapid intravenous administration and/or of hyperkalemia.

Nervous System Disorders: Hyponatremic encephalopathy.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

OVERDOSAGE SECTION

An increased infusion rate of Potassium Chloride in Sodium Chloride Injection, USP can cause:

  • hyperkalemia, manifestations may include disturbances in cardiac conduction and arrhythmias, including bradycardia, heart block, asystole, ventricular tachycardia, ventricular fibrillation.

    The presence of any ECG findings that are suspected to be caused by hyperkalemia should be considered a medical emergency.

    If hyperkalemia is present or suspected, discontinue the infusion immediately and institute close ECG, laboratory and other monitoring and, as necessary, corrective therapy to reduce serum potassium concentrations.

    Muscle weakness (up to and including muscular and respiratory paralysis, paresthesia of extremities) may occur as a complication of hyperkalemia.
  • hyponatremia, manifestations may include seizures, coma, cerebral edema and death.
  • hypernatremia, especially in patients with severe renal impairment.
  • hypotension.
  • gastrointestinal symptoms (ileus, nausea, vomiting, abdominal pain).
  • fluid overload (which can lead to central and/or peripheral edema). See WARNINGS and ADVERSE REACTIONS.

When assessing an overdose, any additives in the solution must also be considered. The effects of an overdose may require immediate medical attention and treatment. Interventions include discontinuation of Potassium Chloride in Sodium Chloride Injection, USP administration, dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid-base balance).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Important Administration Instructions

  • Potassium Chloride in Sodium Chloride Injection, USP is intended for intravenous infusion using sterile equipment.
  • To avoid life threatening hyperkalemia, do not administer Potassium Chloride in Sodium Chloride Injection, USP as an intravenous push (i.e., intravenous injection manually with a syringe connected to the intravenous access) without a quantitative infusion device (see WARNINGS).
  • Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
  • Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
  • Use a dedicated line without any connections to avoid air embolism.
  • Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container.
  • The choice of a central or peripheral venous route of infusion should depend on the osmolarity of the final infusate. Solutions with osmolarity of greater than or equal to approximately 900 mOsm/L must be infused through a central catheter.
  • Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear and container is undamaged.
  • Use of final filter is recommended during administration of all parenteral solutions, where possible.

Dosing Information

SPL UNCLASSIFIED SECTION

The choice of the specific potassium chloride and sodium chloride formulation, dosage, volume, rate and duration of administration is dependent upon the age, weight and clinical and metabolic condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.

Additional electrolyte supplementation may be indicated according to the clinical needs of the patient. Additives can be introduced to the container; however, some additives may be incompatible. Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available.

If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. Discard any unused portion.

Rapid correction of hyponatremia and hypernatremia is potentially dangerous (risk of serious neurologic complications). To avoid complications such as osmotic demyelination syndrome (ODS) during administration, follow the important administration instructions, monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.

HOW SUPPLIED

HOW SUPPLIED SECTION

Potassium Chloride in Sodium Chloride Injection, USP is supplied in single-dose flexible plastic containers as follows:

Product CodeUnit of UseStrengthUnit of Sale
683110 NDC 63323-683-01
One 1000 mL free flex ® bag 		20 mEq Potassium Chloride in 0.45% Sodium Chloride NDC 63323-683-10
Package of 10 free flex ® bags
686110 NDC 63323-686-01
One 1000 mL free flex ® bag 		20 mEq Potassium Chloride in 0.9% Sodium Chloride NDC 63323-686-10
Package of 10 free flex ® bags
688110 NDC 63323-688-01
One 1000 mL free flex ® bag 		40 mEq Potassium Chloride in 0.9% Sodium Chloride NDC 63323-688-10
Package of 10 free flex ® bags

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored between 20ºC to 25°C (68º F to 77°F). [See USP controlled room temperature.]; brief exposure up to 40°C (104°F) does not adversely affect the product.

The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.

INSTRUCTIONS FOR USE:

INSTRUCTIONS FOR USE SECTION

Check flexible container solution composition, lot number, and expiry date.

Do not remove solution container from its overwrap until immediately before use. Use sterile equipment and aseptic technique.

Flexible Plastic Container (free flex ® bag)

To Open

  1. Turn solution container over so that the text is face down. Using the pre-cut corner tabs, peel open the overwrap and remove solution container.
  2. Check the solution container for leaks by squeezing firmly. If leaks are found, or if the seal is not intact, discard the solution.
  3. Do not use if the solution is cloudy or a precipitate is present.

Preparation for Administration

  1. Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from container.
  2. Use a non-vented infusion set or close the air-inlet on a vented set.
  3. Close the roller clamp of the infusion set.
  4. Hold the base of BLUE Infusion Port.
  5. Insert spike through BLUE Infusion Port by rotating wrist slightly until the spike is inserted. NOTE: See full directions accompanying administration set.

To Add Medication Prior to Solution Administration

  1. Identify WHITE Additive Port with arrow pointing toward container.
  2. Immediately before injecting additives, break off WHITE Additive Port Cap with the arrow pointing toward container.
  3. Hold base of WHITE Additive Port horizontally.
  4. Prepare medication site
  5. Insert an 18 to 23 gauge needle horizontally through the center of WHITE Additive Port's septum and inject additives.
  6. Mix container contents thoroughly.

For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To Add Medication During Solution Administration

  1. Close the clamp on the set
  2. Identify WHITE Additive Port with arrow pointing toward container
  3. Immediately before injecting additives, if the Cap has not been broken off, break off WHITE Additive Port cap with the arrow pointing toward container.
  4. Hold base of WHITE Additive Port horizontally.
  5. Prepare medication site.
  6. Using a syringe with an 18 to 23 gauge needle, horizontally insert through the center of WHITE Additive Port's septum and inject additives.
  7. Remove container from IV pole and/or turn to an upright position.
  8. Mix container contents thoroughly.
  9. Using aseptic technique, repeat steps 4-7 as necessary.
  10. Return container to in use position and continue administration.

WARNING: Do not use flexible container in series connections.

Manufactured for:

Fresenius Kabi LogoFresenius Kabi Logo

Lake Zurich, IL 60047
Made in Norway

www.fresenius-kabi.com/us

451701
Issued: February 2021

PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.45% Sodium Chloride Injection, USP Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

freeflex®

NDC 63323-683-01       1000 mL

20 mEq Potassium Chloride

(20 mEq/L)

Potassium Chloride in 0.45% Sodium Chloride

Injection, USP

For Intravenous Use.        Rx only

PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.45% Sodium Chloride Injection, USP Bag Label
PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.45% Sodium Chloride Injection, USP Bag Label

PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.9% Sodium Chloride Injection, USP Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

freeflex®

NDC 63323-686-01       1000 mL

20 mEq Potassium Chloride

(20 mEq/L)

Potassium Chloride in 0.9% Sodium Chloride

Injection, USP

For Intravenous Use.        Rx only

PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.9% Sodium Chloride Injection, USP Bag Label
PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.9% Sodium Chloride Injection, USP Bag Label

PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.9% Sodium Chloride Injection, USP Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

freeflex®

NDC 63323-688-01       1000 mL

40 mEq Potassium Chloride

(40 mEq/L)

Potassium Chloride in 0.9% Sodium Chloride

Injection, USP

For Intravenous Use.        Rx only

PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.9% Sodium Chloride Injection, USP Bag Label
PACKAGE LABEL - PRINCIPAL DISPLAY – Potassium Chloride in 0.9% Sodium Chloride Injection, USP Bag Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
403890potassium chloride 20 MEQ / sodium chloride 0.45 % in 1000 ML InjectionPSN5
637551potassium chloride 20 MEQ / sodium chloride 0.9 % in 1000 ML InjectionPSN5
237367potassium chloride 40 MEQ / sodium chloride 0.9 % in 1000 ML InjectionPSN5
4038901000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML InjectionSCD5
6375511000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML InjectionSCD5
2373671000 ML potassium chloride 0.04 MEQ/ML / sodium chloride 9 MG/ML InjectionSCD5
4038901000 ML K+ Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML InjectionSY5
6375511000 ML K+ Chloride 0.02 MEQ/ML / NaCl 9 MG/ML InjectionSY5
2373671000 ML K+ Chloride 0.04 MEQ/ML / NaCl 9 MG/ML InjectionSY5
4038901000 ML Pot Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML InjectionSY5
6375511000 ML Pot Chloride 0.02 MEQ/ML / NaCl 9 MG/ML InjectionSY5
2373671000 ML Pot Chloride 0.04 MEQ/ML / NaCl 9 MG/ML InjectionSY5
403890potassium chloride 20 MEQ / sodium chloride 0.45 % per 1000 ML InjectionSY5
637551potassium chloride 20 MEQ / sodium chloride 0.9 % per 1000 ML InjectionSY5
237367potassium chloride 40 MEQ / sodium chloride 0.9 % per 1000 ML InjectionSY5

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
63323-683-01Potassium Chloride in Sodium Chloride1000 mL in 1 BAGINJECTION, SOLUTION10005
63323-683-10Potassium Chloride in Sodium Chloride10 in 1 CARTONINJECTION, SOLUTION105
63323-686-01Potassium Chloride in Sodium Chloride1000 mL in 1 BAGINJECTION, SOLUTION10005
63323-686-10Potassium Chloride in Sodium Chloride10 in 1 CARTONINJECTION, SOLUTION105
63323-688-01Potassium Chloride in Sodium Chloride1000 mL in 1 BAGINJECTION, SOLUTION10005
63323-688-10Potassium Chloride in Sodium Chloride10 in 1 CARTONINJECTION, SOLUTION105

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
63323-683POTASSIUM CHLORIDE IN SODIUM CHLORIDE (SODIUM CHLORIDE AND POTASSIUM CHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]5Current NDC, Legacy NDC, 2 package rows20240502_c2467d57-cd2d-4409-bcc0-50128bd01bba.zip
63323-686POTASSIUM CHLORIDE IN SODIUM CHLORIDE (SODIUM CHLORIDE AND POTASSIUM CHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]5Current NDC, Legacy NDC, 2 package rows20240502_c2467d57-cd2d-4409-bcc0-50128bd01bba.zip
63323-688POTASSIUM CHLORIDE IN SODIUM CHLORIDE (SODIUM CHLORIDE AND POTASSIUM CHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]5Current NDC, Legacy NDC, 2 package rows20240502_c2467d57-cd2d-4409-bcc0-50128bd01bba.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
63323-683-01ML - Milliliter63323-683882ccbea-91d2-4abb-b033-9e40653110ef12022-11-07
63323-683-10ML - Milliliter63323-6830fcd3d69-f612-49ac-9fab-86e087d471a012022-11-07
63323-686-01ML - Milliliter63323-68625a06a39-eb26-401d-a485-a2a2956baf7112022-11-07
63323-686-10ML - Milliliter63323-686f0f922bb-5ae1-45e7-8e8b-7504d3e2340312022-11-07
63323-688-01ML - Milliliter63323-688f868f27c-d7c4-40de-b0e4-8f0f252c734712022-11-07
63323-688-10ML - Milliliter63323-6880a443a6f-764e-4cb4-85bd-d188c24951bb12022-11-07

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
63323-68363323-683-01, 63323-683-10
63323-68663323-686-01, 63323-686-10
63323-68863323-688-01, 63323-688-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Name, UNII, Kind table
NameUNIIKind
Sodium Chloride451W47IQ8XACTIB
Potassium Chloride660YQ98I10ACTIB
Sodium Chloride451W47IQ8XACTIB
Potassium Chloride660YQ98I10ACTIB
Sodium Chloride451W47IQ8XACTIB
Potassium Chloride660YQ98I10ACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%POTASSIUM CHLORIDE; SODIUM CHLORIDE150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17
A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%POTASSIUM CHLORIDE; SODIUM CHLORIDE300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17
A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%POTASSIUM CHLORIDE; SODIUM CHLORIDE150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A212347-001AP
A212347-002AP
A212347-003AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 113 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-1784e616aacf4f…
2026-09-14 22:38:342026-08A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-1784e616aacf4f…
2026-09-14 22:38:342026-08A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-0284e616aacf4f…
2026-08-18 06:07:402026-07A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17caaa826d4ba7…
2026-08-18 06:07:402026-07A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17caaa826d4ba7…
2026-08-18 06:07:402026-07A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17011fe1cb6892…
2026-02-19 14:30 UTC2026-02A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17011fe1cb6892…
2026-02-19 14:30 UTC2026-02A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-1731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-1731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-0231067a03dcf5…
2025-08-23 18:47 UTC2025-08A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-176a471c1ec25d…
2025-08-23 18:47 UTC2025-08A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-176a471c1ec25d…
2025-08-23 18:47 UTC2025-08A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-026a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-1703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-1703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-0203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-172680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-172680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-022680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-175bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-175bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-025bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17d06236e962d9…
2024-10-29 15:01 UTC2024-10A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-17d06236e962d9…
2024-10-29 15:01 UTC2024-10A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-02d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-1779d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212347-002POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%300MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2020-09-1779d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212347-003POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%150MG/100ML;900MG/100MLINJECTABLE / INJECTIONAP2021-06-0279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212347-001POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%150MG/100ML;450MG/100MLINJECTABLE / INJECTIONAP2020-09-17301d65b070ca…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 93 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A212347-001AP184e616aacf4f…
2026-09-14 22:38:342026-08A212347-002AP184e616aacf4f…
2026-09-14 22:38:342026-08A212347-003AP184e616aacf4f…
2026-08-18 06:07:402026-07A212347-001AP1caaa826d4ba7…
2026-08-18 06:07:402026-07A212347-002AP1caaa826d4ba7…
2026-08-18 06:07:402026-07A212347-003AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212347-001AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A212347-002AP1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A212347-003AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212347-001AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212347-002AP131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212347-003AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A212347-001AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A212347-002AP16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A212347-003AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212347-001AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212347-002AP1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212347-003AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212347-001AP1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212347-002AP1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212347-003AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212347-001AP103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212347-002AP103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212347-003AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212347-001AP12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212347-002AP12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212347-003AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212347-001AP15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212347-002AP15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212347-003AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212347-001AP1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212347-002AP1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212347-003AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212347-001AP1d06236e962d9…
2024-10-29 15:01 UTC2024-10A212347-002AP1d06236e962d9…
2024-10-29 15:01 UTC2024-10A212347-003AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212347-001AP179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212347-002AP179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212347-003AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212347-001AP1301d65b070ca…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Potassium Chloride in Sodium ChlorideSODIUM CHLORIDE AND POTASSIUM CHLORIDEFresenius Kabi USA, LLCc2467d57-cd2d-4409-bcc0-50128bd01bba2024-04-30Warnings, Adverse reactionsExact identifier
ndc (package): 63323-683-10
ndc (package): 63323-688-01
ndc (package): 63323-686-01
ndc (package): 63323-686-10
ndc (package): 63323-683-01
ndc (package): 63323-688-10
ndc (product): 63323-683
ndc (product): 63323-686
ndc (product): 63323-688
ndc11 (package): 63323068301
ndc11 (package): 63323068610
ndc11 (package): 63323068801
ndc11 (package): 63323068810
ndc11 (package): 63323068601
ndc11 (package): 63323068310
spl id: 23c084c3-6c81-4691-9e86-0c2a17df7076
spl set id: c2467d57-cd2d-4409-bcc0-50128bd01bba

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.